ADM Diagnostics
ADM Diagnostics (ADMdx) applies AI and machine learning to brain PET and MRI imaging to support diagnosis of neurological disorders and to deliver imaging CRO services for CNS clinical trials, serving healthcare providers and pharmaceutical/biotech sponsors.
- Company typePrivate
- Founded2010
- HeadquartersNorthbrook, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What ADM Diagnostics does
ADM Diagnostics, Inc. (operating as ADMdx) is a private neuroimaging analytics company founded in 2010 and headquartered in Northbrook, Illinois. The company applies deep learning, multivariate pattern analysis, and proprietary classifiers to brain PET and MRI scans in order to detect, differentiate, and quantify neurological disorders — including Alzheimer's disease, other dementias, traumatic brain injury, Parkinson's disease, and Down Syndrome-associated AD. Its core diagnostic asset, CorInsights MRI, is an FDA 510(k)-cleared product (December 2021) that quantifies regional brain tissue volumes from a standard T1-weighted MRI scan and compares them against age- and sex-matched normative references.
The platform is anchored by a curated reference database of tens of thousands of PET and MRI scans with linked clinical and fluid biomarker data, and by PipelineMAX — a proprietary image-processing platform with 21 CFR Part 11-compliant audit trails — together with CIReader and CITrials software for centralized reads and trial data management. ADMdx has been granted a patent on a machine learning approach that dissociates co-occurring disease patterns within a single scan, a differentiator supported by 20+ peer-reviewed publications and standards-setting roles co-chaired within RSNA QIBA.
ADMdx operates a dual business model: (1) commercial sales of CorInsights MRI to healthcare networks, where the report is reimbursed under standard CPT codes for the underlying MRI, and (2) professional services for CNS clinical trials, billed per study/milestone, including protocol design, site qualification, central reads, advanced image processing, and endpoint reporting to pharmaceutical and biotech sponsors. Go-to-market is direct enterprise sales to radiologists and neurologists (for CorInsights MRI) and to pharma/biotech sponsors (for trial CRO services), supported by scientific credibility through publications, QIBA leadership, and conference presentations. The company is co-founded and led by CEO Dawn Matthews and CTO Miles Wernick, has 1–10 employees, and has historically been funded primarily through NIH and NSF grants rather than venture capital.
ADM Diagnostics firmographics
Firmographics- Name
- ADM Diagnostics
- Legal name
- ADM Diagnostics, Inc.
- Website
- https://admdx.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ADM Diagnostics (ADMdx) applies AI and machine learning to brain PET and MRI imaging to support diagnosis of neurological disorders and to deliver imaging CRO services for CNS clinical trials, serving healthcare providers and pharmaceutical/biotech sponsors.
- Ownership category
- akta.pro rank
ADM Diagnostics industry classification
Industry- Product category
- Medical Imaging Diagnostics Software
- NAICS
- Medical Laboratories (621511), Scientific Research and Development Services (5417), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Imaging Core Labs & Clinical Endpoint Adjudication (HLAGAEAH), Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where ADM Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Northbrook
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ADM Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Diagnostic Product Sales (CorInsights MRI): Sales of CorInsights MRI, an FDA 510(k)-cleared diagnostic report that provides quantitative brain volume analysis from standard MRI scans to radiologists and neurologists within healthcare networks.
- Clinical Trial Imaging CRO Services: Full-spectrum imaging CRO services for CNS clinical trials including protocol input, imaging site identification and qualification, central reads, advanced image processing and analysis, and reporting. Services are billed per study or per milestone.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Healthcare network deployment of CorInsights MRI with CPT reimbursement |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
ADM Diagnostics product offering
Product offeringCore offering
ADMdx applies AI and machine learning to brain imaging (PET and MRI) to support earlier and more accurate diagnosis of neurological disorders including Alzheimer's disease, other dementias, traumatic brain injury, and Parkinson's disease. Its flagship product, CorInsights MRI, is an FDA 510(k) cleared diagnostic report that quantifies brain tissue volumes from standard T1-weighted MRI scans and compares them to age- and sex-matched normative references. The company also provides full-spectrum imaging CRO services for CNS clinical trials, including protocol input, site qualification, central reads, advanced image processing, and reporting.
Product overview
ADMdx offers a platform approach centered on CorInsights MRI, an FDA 510(k) cleared diagnostic product, supported by imaging CRO services for clinical trials, and powered by proprietary AI technology including PipelineMAX, CIReader, and CITrials software tools. The company provides a full spectrum of imaging services for CNS clinical trials using PET and MRI biomarkers.
Differentiator
Problem solved
Functional benefit
Brands
- CorInsights MRI: FDA 510(k) cleared diagnostic report providing quantitative brain volume insights using standard MRI scans to support medical professionals in diagnosis of brain disorders
Products and services
- CorInsights MRI FDA 510(k) cleared diagnostic report that quantifies brain tissue volumes from standard T1-weighted MRI scans and compares them to age- and sex-matched normative references, intended as an adjunct to clinical assessment for radiologists and neurologists diagnosing brain disorders including Alzheimer's disease and other dementias.
- Clinical Trial Imaging CRO Services Full-spectrum imaging CRO services for CNS clinical trials using PET and MRI biomarkers, including protocol input, charter and technical manual development, imaging site identification and qualification, central data receipt and quality control, radiology reads, advanced image processing and analysis, reporting, data management, and archival. Services support patient inclusion, stratification, treatment effect detection, and treatment responder characterization for pharmaceutical and biotech sponsors.
Quantifiable outcome
- ADMdx identified significant treatment effects upon glucose metabolism in brain regions affected in AD (posterior cingulate and precuneus) in a Riluzole study
- +5 more outcomes
Companies that use ADM Diagnostics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
ADM Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature7 records
ADM Diagnostics partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- University of Arizona Center for Innovation in Brain Science (Dr. Roberta Brinton)coreCollaboration on Phase I and Phase II clinical trials of Allopregnanolone (Allo) in Parkinson's disease and mild Alzheimer's disease patients. ADMdx provided DaTscan image analysis measuring dopamine transporters and CorInsights MRI reports quantifying regional brain volumes, demonstrating favorable effects on multiple measures.
- Dr. Yu-Chien Wu / CARE ConsortiumminorCollaboration through the Concussion Assessment, Research and Education (CARE) Consortium for imaging data from college contact sport athletes, contributing to the comprehensive dataset used in developing diagnostic tools for repetitive head impact effects.
- Dr. Aaron Ritter / Hoag Pickens Neuroscience InstituteminorCollaboration within the RHI diagnostic development program, contributing to the network of collaborators working to detect and differentiate the effects of repetitive head impact from other dementias.
- Dr. Jeffrey Cummings and Dr. Jefferson KinneycoreCollaboration on published work demonstrating relationships between blood biomarkers and brain imaging in Alzheimer's disease patients. Results published in Journal of Alzheimer's & Dementia: TRCI (July 2024), showing correlations between plasma biomarkers and FDG PET, tau PET, and volumetric MRI.
- Cleveland Clinic Lou Ruvo Center for Brain Health (Dr. Charles Bernick)coreCollaboration on the Professional Athletes Brain Health Study (PABHS), which has acquired brain images and data from over 750 boxers, mixed martial artists, and other contact sport athletes across more than 1,900 visits. Dr. Bernick serves as PI. Data supports development of diagnostic tools to detect repetitive head impact effects and differentiate them from Alzheimer's disease.
- Boston University / DIAGNOSE-CTE Study (Dr. Robert Stern)coreCollaboration on the DIAGNOSE-CTE study of retired National Football League and college football players. Dr. Stern serves as lead PI. Combined data from this study and PABHS represents an unprecedented dataset for understanding the effects of repetitive head impact on the brain.
- Radiological Society of North America / QIBAcoreADMdx CEO Dawn Matthews co-chairs both the QIBA Amyloid PET Working Group and the QIBA Tau PET Working Group. These groups develop industry profiles for reliable quantitative measurement of amyloid and tau PET imaging, reducing variability in clinical trials and clinical practice.
- Siemens Healthineers (Anne Smith)coreAnne Smith of Siemens Healthineers co-chaired the QIBA Amyloid PET Working Group alongside ADMdx CEO Dawn Matthews, collaborating on multi-year work that defined criteria for PET image acquisition and measurement to reduce variability in amyloid PET imaging.
- Cerveau TechnologiescoreCo-lead authorship on published paper describing visual read method for Cerveau's MK-6240 tau PET tracer. ADMdx classified 1,842 scans using the method, representing the most scans read by a single entity, and contributed to research supporting the tracer's clinical utility.
- Mount Sinai Medical Center and Rockefeller University (Dr. Ana Pereira)coreCollaborative study on the effects of Riluzole (a glutamate modulator) on brain metabolism and cognition in Alzheimer's disease patients. ADMdx provided FDG PET image analysis demonstrating favorable treatment effects in the precuneus and posterior cingulate. Results were published in Brain journal.
- Weill Cornell School of Medicine (Dr. Lisa Mosconi)coreCollaboration studying effects of diet, exercise, sex, menopause, and family history upon risk for Alzheimer's disease. Studies demonstrated that Mediterranean diet adherence and exercise mitigate AD risk as measured by imaging biomarkers, and that menopause is associated with brain biomarker changes suggesting vulnerability to AD.
- UCSD / USC (Dr. Michael Rafii)coreCollaboration applying multivariate machine learning to detect Alzheimer's disease progression in adults with Down Syndrome. Using a single FDG PET or MRI scan, ADMdx dissociated effects of Down Syndrome from AD, with results correlating to amyloid, tau, and cognitive endpoints.
- Washington University School of Medicine (Dr. Tammie Benzinger)coreCollaboration applying multivariate machine learning to determine patterns of glucose hypometabolism and brain atrophy associated with the emergence of AD in Dominantly Inherited Alzheimer's Disease (DIAN) patients. Pattern scores correlated with clinical decline and emerged prior to symptom onset.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
ADM Diagnostics competitors and assessment
Company assessmentDirect peers
- Ixico: Ixico provides AI-driven brain imaging analytics and imaging CRO services for CNS clinical trials in Alzheimer's, Parkinson's, and Huntington's — overlapping directly with ADMdx's trial services and biomarker business.
- icometrix: icometrix develops FDA-cleared AI-based brain MRI quantification tools (icobrain) for multiple sclerosis, dementia, and traumatic brain injury — the most direct commercial competitor to ADMdx's CorInsights MRI in volumetric brain analysis for neurodegenerative disease diagnosis.
- Biospective: Biospective is a CRO specializing in CNS imaging biomarkers and clinical trial image analysis for AD, PD, MS, and oncology — closely comparable to ADMdx's imaging CRO offering and reference-database-driven analytics.
- Cerveau Technologies: Cerveau develops and supplies tau PET ligands (MK-6240, PI-2620) and partners with imaging CROs — both an ADMdx collaboration partner and a partial competitor in the tau PET imaging services value chain.
- Cortechs.ai (CorTechs Labs / NeuroQuant): Cortechs.ai markets NeuroQuant, the leading FDA-cleared brain MRI volumetric measurement product used by radiologists for hippocampal and atrophy analysis — directly competing with ADMdx's CorInsights MRI in clinical radiology workflow.
- Invicro: Invicro (now part of Cerveau Technologies) provides preclinical and clinical imaging services with strong CNS and PET expertise, including tau PET ligands — overlapping with ADMdx's tau PET read work and CRO services.
Emerging players
- QMENTA: QMENTA provides a cloud-based neuroimaging platform for clinical trials and research, including AI-based brain quantification — comparable to ADMdx's PipelineMAX and CIReader tooling for trial image management.
- Life Molecular Imaging: Life Molecular Imaging (formerly Piramal Imaging) supplies amyloid and tau PET tracers (e.g., florbetapir, flortaucipir) and offers imaging services — adjacent overlap with ADMdx's PET-based AD diagnostic and trial work.
Broad incumbents
- Siemens Healthineers: Siemens Healthineers is a major medical imaging hardware and software vendor with PET/MRI scanners and AI imaging offerings. Anne Smith co-chairs the QIBA Amyloid PET group with ADMdx's CEO and is a collaboration partner, but the broader organization competes in adjacent AI imaging spaces.
- Clario: Clario (formed from ERT/Bioclinica merger) is a large clinical trial technology and imaging CRO offering broad CNS imaging services. Larger and broader than ADMdx, but competes for the same pharma trial-imaging budgets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ADM Diagnostics social profiles
Digital presenceADM Diagnostics compliance and trust
Trust signalCompliance2 records
ADM Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADM Diagnostics leadership team
Management profileNumber of profiles
Profiles8 records
ADM Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADM Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADM Diagnostics
What does ADM Diagnostics do?
ADMdx applies AI and machine learning to brain imaging (PET and MRI) to support earlier and more accurate diagnosis of neurological disorders including Alzheimer's disease, other dementias, traumatic brain injury, and Parkinson's disease. Its flagship product, CorInsights MRI, is an FDA 510(k) cleared diagnostic report that quantifies brain tissue volumes from standard T1-weighted MRI scans and compares them to age- and sex-matched normative references. The company also provides full-spectrum imaging CRO services for CNS clinical trials, including protocol input, site qualification, central reads, advanced image processing, and reporting.
Is ADM Diagnostics a public or private company?
ADM Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ADM Diagnostics founded?
ADM Diagnostics was founded in 2010. It employs 1 to 10 people.
Where is ADM Diagnostics based?
ADM Diagnostics is headquartered in Northbrook, United States, in the North America region.
How does ADM Diagnostics make money?
Two revenue lines are on record. Diagnostic Product Sales (CorInsights MRI) is the primary driver. The others are clinical Trial Imaging CRO Services.
Who are ADM Diagnostics's main competitors?
Direct peers on record are Ixico, icometrix, Biospective, Cerveau Technologies, Cortechs.ai (CorTechs Labs / NeuroQuant) and Invicro. Emerging players are QMENTA and Life Molecular Imaging. Broad incumbents are Siemens Healthineers and Clario.
Does ADM Diagnostics have an API?
No public API is recorded for ADM Diagnostics.
What industry is ADM Diagnostics in?
ADM Diagnostics's product category is Medical Imaging Diagnostics Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 621511 and its SIC code is 8731.